-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Revumenib Citrate in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Revumenib Citrate in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Revumenib Citrate in Metastatic Colorectal Cancer Drug Details: Revumenib citrate...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Revumenib Citrate in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Revumenib Citrate in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Revumenib Citrate in Solid Tumor Drug Details: Revumenib citrate (SNDX-5613) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Axatilimab in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Axatilimab in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Axatilimab in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Axatilimab (SNDX-6352)...
-
Thematic Analysis
NewState of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence
Reasons to buy the ‘State of the Biopharmaceutical Industry 2024’ thematic intelligence report: Highlight the business environment and the industry, regulatory, and macroeconomic trends that are going to shape the biopharmaceutical industry in the next 12 months. Benchmark the impact of major themes on the biopharmaceutical industry in the next 12 months, Identify themes that will have the greatest positive or negative impact in the coming months. Comprehend the opinions of industry respondents on these themes. Predict the industry’s growth prospects...
-
Company Insights
Innovation and Patenting activity of Syndax Pharmaceuticals Inc Q1 2024
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Syndax Pharmaceuticals Inc Q1 2024". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewHodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024
Empower your strategies with our Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) – Drugs In Development, 2024 report and make more profitable business decisions. Hodgkin lymphoma is a cancer that starts in white blood cells called lymphocytes. Symptoms include painless swelling of the lymph nodes in the neck, armpits, or groin, fever and chills, night sweats, weight loss, loss of appetite, and itchy skin. Hodgkin lymphoma is most common among people ages 15 to 35 and 50 to 70. Past infections with the...
-
Product Insights
NewGraft Versus Host Disease (GVHD) – Drugs In Development, 2024
Empower your strategies with our Graft Versus Host Disease (GVHD) – Drugs In Development, 2024 report and make more profitable business decisions. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps; nausea, vomiting, and diarrhea; dry or irritated eyes; jaundice; shortness of breath; vaginal dryness; and weight loss. Treatment includes immunosuppressants. The Graft Versus Host...
-
Product Insights
NewBone Marrow Transplant Rejection – Drugs In Development, 2024
Empower your strategies with our Bone Marrow Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain, and shortness of breath. Treatment includes immunosuppressive drugs. The Bone Marrow Transplant...
-
Product Insights
NewInterstitial Lung Fibrosis – Drugs In Development, 2024
Empower your strategies with our Interstitial Lung Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Interstitial Lung Fibrosis or interstitial lung disease (ILD) is a group of diseases that cause scarring of the lungs (fibrosis) or lung parenchyma. If untreated it can lead to respiratory failure and death. Symptoms start with inflammation and can result in bronchiolitis, vasculitis, and alveolitis. Exposure to hazardous chemicals or materials like asbestos, hypersensitivity, drug-induced, underlying autoimmune conditions, family history, smoking,...